4613-C CLINICAL, GENETIC, AND PATHOLOGIC FEATURES, TREATMENT, AND LONG-TERM OUTCOME IN PATIENTS WITH BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS: A MULTICENTER STUDY IN JAPAN Ken Kato 1 , Shuichiro Umetsu 2 , Takao Togawa 3 , Koichi Ito 3 , Takayoshi Kawabata 4 , Teruko Arinaga-Hino 1 , Naoya Tsumura 1 , Ryosuke Yasuda 1 , Yutaro Mihara 1 , Hironori Kusano 1 , Shogo Ito 3 , Kazuo Imagawa 5 , Hisamitsu Hayashi 6 , Ayano Inui 2 , Yushiro Yamashita 1 and Tatsuki Mizuochi 1 , (1)Kurume University School of Medicine, (2)Saiseikai Yokohamashi Tobu Hospital, (3)Nagoya City University Graduate School of Medical Sciences, (4)Ishikawa Prefectural Central Hospital, (5)University of Tsukuba, (6)The University of Tokyo Background: There have been few reports of benign recurrent intrahepatic cholestasis (BRIC) from East Asia
Mitochondrial superoxide mediates labile iron level: evidence from Mn-SOD-transgenic mice and heterozygous knockout mice and isolated rat liver mitochondria
However, the bioavailability of isothiocyanates was found to be much lower with the consumption of broccoli supplements devoid of myrosinase than with the consumption of fresh broccoli sprouts
[1] There is no official clinical guidance regarding the concurrent use of lipotropic injections with tirzepatide, as Lipo C formulations are unapproved compounded products that have not been reviewed by the FDA
Changes in PGK1 activity directly impact glycolytic flux and cellular energy metabolism
